Ulcerative Colitis

According to published studies¹, individuals in the top 30% of the polygenic risk score (PRS) have a 4.44 times greater likelihood of developing ulcerative colitis compared to those in the lowest genetic risk group—especially if they follow an unhealthy dietary pattern. However, a personalized diet, avoiding smoking, regular exercise, and maintaining a healthy weight can significantly reduce the risk of developing the disease and help manage symptoms.

The GENOSOPHY® genetic test offers an advanced assessment of the genetic risk for ulcerative colitis, analyzing 42 genetic loci through GENOSOPHY®’s award-winning algorithm, ensuring high accuracy in risk prediction.

Conditions Covered by the Test

This test determines the relative risk for ulcerative colitis in the general population and is recommended for:

• Individuals with a family history of ulcerative colitis
• People who present symptoms related to the condition and wish to assess their genetic risk

Clinical Benefits of GENOSOPHY®’s Polygenic Risk Score

Diagnosis

• More accurate estimation of genetic risk for ulcerative colitis, providing complementary insights for clinical evaluation

Prognosis

• Enables early selection of preventive strategies through specialized protocols², with recent studies showing that a healthy lifestyle can halve the genetic risk for the disease¹

Management

• Supports the development of personalized dietary and lifestyle interventions for optimal disease control

Testing Process

• Saliva sample collection
• Analysis of 42 genetic variants and risk calculation via the award-winning GENOSOPHY® algorithm
• Results delivered within 5–6 weeks

Supplementary Services

Based on your results and genetic profile, GENOSOPHY® offers the following services to maximize the impact of your preventive plan:

• Genetic counseling
• Customized nutrition plan based on your genetic profile
• Nutritional consultation

Selected References

1. Sun Y et al., Am J Gastroenterol 2023 Mar 1;118(3):511–522. DOI: 10.14309/ajg.0000000000002180

Pardali et al., Metabol Open 2024 Dec 30;25:100342. DOI: 10.1016/j.metop.2024.100342